METTL3/MALAT1/ELAVL1 Axis Promotes Tumor Growth in Ovarian Cancer

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A, Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Saani I, Raj N, Sood R, et al. Clinical challenges in the management of malignant ovarian germ cell tumours. Int J Environ Res Public Health. 2023;20(12):6089. doi:10.3390/ijerph20126089
   PubMedGoogle Scholar
• Sehouli J, Grabowski J. Surgery in recurrent ovarian cancer. Cancer. 2019;125(24):4598–4601. doi:10.1002/cncr.32511
   PubMedGoogle Scholar
• Arend R, Martinez A, Szul T, et al. Biomarkers in ovarian cancer: to be or not to be. Cancer. 2019;125(24):4563–4572. doi:10.1002/cncr.32595
   PubMedGoogle Scholar
• Shah S, Cheung A, Kutka M, et al. Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health. 2022;19(13):8113. doi:10.3390/ijerph19138113
   PubMed Web of Science ®Google Scholar
• Pavlidis N, Rassy E, Vermorken JB, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021;75:102045. doi:10.1016/j.canep.2021.102045
   PubMed Web of Science ®Google Scholar
• Luvero D, Plotti F, Aloisia A, et al. Ovarian cancer relapse: from the latest scientific evidence to the best practice. Crit Rev Oncol Hematol. 2019;140:28–38. doi:10.1016/j.critrevonc.2019.05.014
   PubMed Web of Science ®Google Scholar
• Revythis A, Limbu A, Mikropoulos C, et al. Recent insights into PARP and immuno-checkpoint inhibitors in epithelial ovarian cancer. Int J Environ Res Public Health. 2022;19(14):8577. doi:10.3390/ijerph19148577
   PubMed Web of Science ®Google Scholar
• Bonifácio VDB. Ovarian cancer biomarkers: moving forward in early detection. Adv Exp Med Biol. 2020;1219:355–363.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang Y, Zou C, et al. Tumor-associated macrophages facilitate the proliferation and migration of cervical cancer cells. Oncologie. 2022;24(1):147–161. doi:10.32604/oncologie.2022.019236
   Web of Science ®Google Scholar
• Ghose A, Gullapalli SVN, Chohan N, et al. Applications of proteomics in ovarian cancer: dawn of a New Era. Proteomes. 2022;10(2):16. doi:10.3390/proteomes10020016
   PubMed Web of Science ®Google Scholar
• He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176. doi:10.1186/s12943-019-1109-9
   PubMed Web of Science ®Google Scholar
• Yao W, Bin Q, Shen H, Deng H, Tang F. Serum level of tumor-specific growth factor in patients with cervical cancer and its potential prognostic role. Oncologie. 2022;24(3):499–512. doi:10.32604/oncologie.2022.024951
   Web of Science ®Google Scholar
• Jiang X, Liu B, Nie Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6(1):74. doi:10.1038/s41392-020-00450-x
   PubMed Web of Science ®Google Scholar
• Chen J, Guo B, Liu X, et al. Roles of N(6)-methyladenosine (m(6)A) modifications in gynecologic cancers: mechanisms and therapeutic targeting. Exp Hematol Oncol. 2022;11(1):98. doi:10.1186/s40164-022-00357-z
   PubMed Web of Science ®Google Scholar
• Zeng C, Huang W, Li Y, et al. Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020;13(1):117. doi:10.1186/s13045-020-00951-w
   PubMed Web of Science ®Google Scholar
• Liu S, Zhuo L, Wang J, et al. METTL3 plays multiple functions in biological processes. Am J Cancer Res. 2020;10(6):1631–1646.
   PubMed Web of Science ®Google Scholar
• Han J, Wang J-Z, Yang X, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18(1):110. doi:10.1186/s12943-019-1036-9
   PubMed Web of Science ®Google Scholar
• Peng W, Li J, Chen R, et al. Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway. J Exp Clin Cancer Res. 2019;38(1):393. doi:10.1186/s13046-019-1408-4
   PubMed Web of Science ®Google Scholar
• Wang Q, Guo X, Li L, et al. N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis. 2020;11(10):911. doi:10.1038/s41419-020-03071-y
   PubMed Web of Science ®Google Scholar
• Yuan C, Zhu X, Han Y, et al. Elevated HOXA1 expression correlates with accelerated tumor cell proliferation and poor prognosis in gastric cancer partly via cyclin D1. J Exp Clin Cancer Res. 2016;35:15. doi:10.1186/s13046-016-0294-2
   PubMed Web of Science ®Google Scholar
• Bi X, Lv X, Liu D, et al. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway. Cancer Gene Ther. 2021;28(3–4):335–349. doi:10.1038/s41417-020-00222-3
   PubMed Web of Science ®Google Scholar
• Cui S. METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway. J Clin Lab Anal. 2022;36(12):e24761. doi:10.1002/jcla.24761
   PubMed Web of Science ®Google Scholar
• Aliyuda F, Moschetta M, Ghose A, et al. Advances in ovarian cancer treatment beyond PARP inhibitors. Curr Cancer Drug Targets. 2023;23(6):433–446. doi:10.2174/1568009623666230209121732
   PubMed Web of Science ®Google Scholar
• Hua W, Zhao Y, Jin X, et al. METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol Oncol. 2018;151(2):356–365. doi:10.1016/j.ygyno.2018.09.015
   PubMed Web of Science ®Google Scholar
• Choe J, Lin S, Zhang W, et al. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. 2018;561(7724):556–560. doi:10.1038/s41586-018-0538-8
   PubMed Web of Science ®Google Scholar
• Liang S, Guan H, Lin X, et al. METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway. Oncol Lett. 2020;19(4):3197–3204. doi:10.3892/ol.2020.11425
   PubMed Web of Science ®Google Scholar
• Jin D, Guo J, Wu Y, et al. m(6)A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2019;12(1):135. doi:10.1186/s13045-019-0830-6
   PubMed Web of Science ®Google Scholar
• Li S, Jiang F, Chen F, et al. Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on Adriamycin resistance in breast cancer. J Biochem Mol Toxicol. 2022;36(1):e22922. doi:10.1002/jbt.22922
   PubMed Web of Science ®Google Scholar
• Visvanathan A, Patil V, Arora A, et al. Essential role of METTL3-mediated m(6)A modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2018;37(4):522–533. doi:10.1038/onc.2017.351
   PubMed Web of Science ®Google Scholar
• Linares CA, Varghese A, Ghose A, et al. Hallmarks of the tumour microenvironment of gliomas and its interaction with emerging immunotherapy modalities. Int J Mol Sci. 2023;24(17):13215. doi:10.3390/ijms241713215
   PubMed Web of Science ®Google Scholar
• Wang Q, Geng W, Guo H, et al. Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer. J Hematol Oncol. 2020;13(1):57. doi:10.1186/s13045-020-00895-1
   PubMed Web of Science ®Google Scholar
• Meyer KD, Saletore Y, Zumbo P, et al. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell. 2012;149(7):1635–1646. doi:10.1016/j.cell.2012.05.003
   PubMed Web of Science ®Google Scholar
• Yang H. Comprehensive analysis of the expression and clinical significance of a ferroptosis-related genome in ovarian serous cystadenocarcinoma: a study based on TCGA data. Oncologie. 2022;24(4):835–863. doi:10.32604/oncologie.2022.026447
   Web of Science ®Google Scholar
• Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharmacother. 2019;112:108613. doi:10.1016/j.biopha.2019.108613
   PubMed Web of Science ®Google Scholar